Wednesday, June 10, 2026

The Most Lucrative Biosimilar Insulin Opportunity May Not Be the Biggest One

›
The race to develop biosimilar or follow-on biologic entrants in the U.S. insulin market has suffered from a fundamental strategic flaw: cha...
Tuesday, May 12, 2026

With UNH's Optum Rx Reforms, The Last Big PBM Domino Is Falling

›
Bloomberg health care reporter John Tozzi reported on LinkedIn (the link he shared is at https://www.bloomberg.com/news/articles/2026-05-11...
Monday, May 04, 2026

FDA Approves Yet Another Glargine Insulin Biosimilar from Lannett Company/HEC

›
Today, there was a press release (see  https://www.businesswire.com/news/home/20260504761789/en/Lannett-Company-Lanexa-Biologics-and-Sunshin...
Monday, April 06, 2026

PBM Formulary Exclusions Are Going Away, Ending "Not Covered" By Your Insurance

›
For years, people with Type 1 diabetes in the United States have been told some version of the same thing at the pharmacy counter: that'...
Thursday, March 19, 2026

Unbranded Humalog Is Cheap on TrumpRx—And GoodRx Enables It.

›
  Back on January 27, 2026, the Office of Inspector General ("OIG") for the U.S. Department of Health and Human Services ("HH...
Tuesday, March 03, 2026

Comment until March 16, 2026 on FTC-Express Scripts Proposed Settlement Agreement

›
Today, I am opining on the recent proposed "settlement" agreement with the Federal Trade Commission (FTC) and Cigna's Evernort...
Friday, February 20, 2026

We Already Have Generic GLP-1s. Why Don't Prices Reflect That? Answer: PBM Pricing Arbitrage.

›
The focus of this blog is the autoimmune form of diabetes known as Type 1 diabetes (T1D), which has exactly one FDA-approved treatment (insu...
Thursday, January 22, 2026

Calling All Hackers: Find a Way to Enable Patients to Have Alarms and Share Dexcom Stelo or Abbott Lingo Readings With Others and You Might Just Have a Business!

›
Back on August 26, 2024, Dexcom, Inc. introduced its first over‑the‑counter (OTC) continuous glucose monitor branded as the Dexcom Stelo (se...